FDA Cites Reliance Life Sciences Private Limited in 2026-08-18 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
**FDA Warning Letter | Reliance Life Sciences Private Limited | CGMP Violations | August 18, 2026** The FDA's Center for Drug Evaluation and Research (CDER) cited Reliance Life Sciences Private Limited (FEI 3009510975, Navi Mumbai, India) for significant Current Good Manufacturing Practice violations observed during an inspection conducted February 19–27, 2026. Violations include: inaccurate microbiology laboratory records with undocumented samples and missing dilution factors in microbial limit testing, rendering batch conformance to specifications scientifically unsupported; and inadequate electronic records controls allowing deletion or overwriting of integrity testing data without unique file naming or documentation of failed tests, compromising data reliability and product safety assurance. The FDA stated that drug products manufactured under these conditions are adulterated and that failure to promptly address violations may result in regulatory action without further notice.
Argus analysis
# FDA Warning Letter Analysis: Reliance Life Sciences Private Limited
**Company and Violations**
Reliance Life Sciences Private Limited, a pharmaceutical manufacturer in Navi Mumbai, India (FEI 3009510975), received a warning letter from FDA's Center for Drug Evaluation and Research on August 18, 2026, following a February 2026 inspection. The FDA documented significant Current Good Manufacturing Practice (CGMP) violations in finished pharmaceutical manufacturing. The agency determined that the firm's methods, facilities, and controls do not conform to CGMP requirements, rendering drug products adulterated under the Federal Food, Drug, and Cosmetic Act.
**Regulatory Citations and Meaning**
The violations center on 21 CFR parts 210 and 211, which establish CGMP standards for finished pharmaceuticals. Specifically, the firm violated 21 CFR 211.194(a) regarding laboratory records. Inspectors documented systematic failures in microbiology testing documentation: samples were recorded as collected and incubated when they had not been collected; colony-forming unit counts lacked required dilution factors; and electronic records controls failed to preserve data integrity, allowing deletion or overwriting of critical container-closure integrity testing results. These violations indicate compromised data reliability and undermine the quality unit's ability to ensure batch conformity before distribution.
**Response Timeline and Industry Watch Points**
Reliance submitted a March 20, 2026 response to the FDA Form 483, which the agency found inadequate for lacking specific timelines, defined accountability measures, and sufficient scope. Compliance officers should monitor for: a detailed data integrity investigation protocol addressing all laboratories and systems; retrospective review of microbial limit tests currently distributed in the U.S. market; comprehensive risk assessment of patient safety impacts; and a formal corrective action plan with measurable deliverables. Future enforcement actions could include product seizures or import detention if remediation proves insufficient.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Reliance Life Sciences Private Limited MARCS-CMS 730801 — August 18, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Reference #: 320-26-117 Product: Drugs Recipient: Recipient Name Mr. Santhosh Mathai Recipient Title Business Head-Pharmaceuticals Reliance Life Sciences Private Limited Dhirubhai Ambani Life Sciences Centre R-282 Ttc Area of MIDC, Thane Belapur Road, Rabale Navi Mumbai 400701 Maharashtra India (b)(6) Issuing Office: Center for Drug Evaluation and Research (CDER) United States August 18, 2026 WARNING LETTER Reference number: 320-26-117 To Mr. Santhosh Mathai: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice. FDA Inspection Violations were observed and documented during an inspection of your drug manufacturing facility, Reliance Life Sciences Private Limited, FDA Establishment Identifier (FEI) 3009510975, at Dhirubhai Ambani Life Sciences Centre, R-282 Ttc Area Of MIDC, Thane Belapur Road, Rabale, Navi Mumbai, Maharashtra, 400701 India, from February 19 to February 27, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your March 20, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our inspection. As a reminder, this is not an all-inclusive list of violations at your facility. 1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)). Inaccurate Microbiology Laboratory Records You failed to accurately doc…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Reliance Life Sciences Private Limited had FDA enforcement actions before?
- Yes. Argus HQ has recorded 5 total FDA actions tied to Reliance Life Sciences Private Limited: 1 warning letter, 4 recalls, and 0 approval records.
- What FDA violations was Reliance Life Sciences Private Limited cited for?
- The FDA Warning Letter to Reliance Life Sciences Private Limited (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/Finished Pharmaceuticals/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites Reliance Life Sciences Private Limited in 2026-08-18 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-reliance-life-sciences-private-limited-2026-08-18-cgmp
"FDA Cites Reliance Life Sciences Private Limited in 2026-08-18 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-reliance-life-sciences-private-limited-2026-08-18-cgmp.
Argus HQ Research. "FDA Cites Reliance Life Sciences Private Limited in 2026-08-18 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire Holdings LLC. Accessed September 2, 2026. https://argushq.ai/fda/warning-letter/fda-wl-reliance-life-sciences-private-limited-2026-08-18-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_reliance_life_sciences_private_limited_2026_08_18_cgmp_2026,
title = {FDA Cites Reliance Life Sciences Private Limited in 2026-08-18 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-reliance-life-sciences-private-limited-2026-08-18-cgmp},
note = {Accessed: September 2, 2026}
}